RBC Bioscience

RBC Bioscience EBIT Margin

The EBIT Margin (Operating Margin) of RBC Bioscience (6848.TWO) as of Nov 5, 2026 is 17.44 %. In the previous year, EBIT Margin (Operating Margin) was 8.43 % — a change of 106.90% (higher).

EBIT Margin

17.44 %

YoY

106.90%

Last updated:

EBIT Margin (Operating Margin) of RBC Bioscience is 2024 17.44 % . EBIT Margin (Operating Margin) of RBC Bioscience was 2023 8.43 % . It decreases by 106.90% higher compared to the previous year.

RBC Bioscience's operating (EBIT) margin stands at 17.4%, down from 32.8% several years earlier.

The RBC Bioscience EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
11.19 TWD
Jan 1, 2019
12.07 TWD
Jan 1, 2020
32.75 TWD
Jan 1, 2021
19.35 TWD
Jan 1, 2022
4.46 TWD
Jan 1, 2023
8.43 TWD
Jan 1, 2024
17.44 TWD
The RBC Bioscience EBIT Margin history
YEAREBIT MarginYoY
17.44 %+106.90%
8.43 %+89.15%
4.46 %-76.97%
19.35 %-40.91%
32.75 %+171.31%
12.07 %+7.84%
11.19 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

EBIT Margin (Operating Margin) of RBC Bioscience is 17.44 % in 2024.

EBIT Margin (Operating Margin) of RBC Bioscience changed from 8.43 % to 17.44 %, representing a 106.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s RBC Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — RBC Bioscience

All Key Metrics — RBC Bioscience